Adrenaline Auto-Injectors for Preventing Fatal Anaphylaxis

Area of Science:

• Immunology
• Pharmacology
• Public Health

Background:

• Anaphylaxis, a severe allergic reaction, affects up to 5% of the population.
• While often resolving without lasting physical harm, anaphylaxis can lead to significant anxiety and reduced quality of life.
• Fatal outcomes from anaphylaxis, though rare, can occur unpredictably in the community.

Purpose of the Study:

• To evaluate the effectiveness of adrenaline autoinjectors (AAIs) in preventing fatal anaphylaxis.
• To analyze data from animal and human studies, as well as epidemiological evidence, regarding AAI efficacy.
• To identify potential limitations of current AAIs and explore alternative treatment strategies.

Main Methods:

• Review of in vivo animal and human studies on adrenaline administration.
• Analysis of epidemiological data on AAI prescription rates and fatal anaphylaxis.
• Pharmacokinetic and pharmacodynamic assessment of adrenaline delivery via different routes.

Main Results:

• Intravenous adrenaline infusions effectively reverse anaphylaxis, requiring sustained doses.
• Intramuscular adrenaline from AAIs achieves temporary peak plasma levels but can be short-lived and unpredictable.
• Epidemiological data show no clear link between increased AAI prescriptions and decreased fatal anaphylaxis rates.

Conclusions:

• Current AAIs may have limited impact on fatal anaphylaxis due to insufficient sustained adrenaline concentrations.
• The effectiveness of AAIs on quality of life is variable.
• There is a need for alternative methods that can safely provide sustained adrenaline infusion for anaphylaxis treatment.